Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
To read the full story
Related Article
- Nihon Servier Launches Blood Cancer Med Oncaspar in Japan
October 3, 2023
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
- Novo’s Obesity Med Wegovy Skips Listing Again in August
August 24, 2023
REGULATORY
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
March 13, 2025
- MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
March 13, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…